PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?

NAMPT, also known as pre-B-cell colony-enhancing factor and visfatin, has been proposed to be involved in preventing apoptosis in cancer cells and, as such, has received a great deal of attention in recent years and stimulated the development to specific inhibitors for treating cancer. The role of NAMPT inhibitors as potential therapeutic agents for other diseases has not been studied extensively. Here, we describe their applicability for treating rheumatoid arthritis. We summarize current knowledge of NAMPT expression in healthy and diseased tissues, thereafter, we focus on pathological mechanisms relevant to rheumatoid arthritis that involve the NAMPT pathway and review the current status of NAMPT inhibitors being evaluated in clinical trials.

[1]  U. Ceglarek,et al.  Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes , 2012, Innate immunity.

[2]  R. Loeser,et al.  Extracellular nicotinamide phosphoribosyltransferase (NAMPT/visfatin) inhibits insulin-like growth factor-1 signaling and proteoglycan synthesis in human articular chondrocytes , 2012, Arthritis Research & Therapy.

[3]  V. Baichwal,et al.  Abstract B137: Pharmacokinetics, antitumor activity, and therapeutic index of Nampt inhibitor MPC-8640 in mice. , 2011 .

[4]  Yulin Li,et al.  Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: A possible cause for reduced osteogenesis and increased adipogenesis in older individuals , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  D. Toiber,et al.  Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. , 2011, Endocrinology.

[6]  H. Tilg,et al.  A key role for Pre–B cell colony–enhancing factor in experimental hepatitis , 2011, Hepatology.

[7]  Michael Detmar,et al.  SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance , 2011, Annals of the rheumatic diseases.

[8]  J. Vencovský,et al.  The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy. , 2011, Cytokine.

[9]  Simon A. Jones,et al.  Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. , 2011, Arthritis and rheumatism.

[10]  Su-Jae Lee,et al.  Nicotinamide Phosphoribosyltransferase Is Essential for Interleukin-1β-mediated Dedifferentiation of Articular Chondrocytes via SIRT1 and Extracellular Signal-regulated Kinase (ERK) Complex Signaling* , 2011, The Journal of Biological Chemistry.

[11]  J. Marshall,et al.  Pre-B Cell Colony-Enhancing Factor (PBEF/Nampt/Visfatin) Primes Neutrophils for Augmented Respiratory Burst Activity through Partial Assembly of the NADPH Oxidase , 2011, The Journal of Immunology.

[12]  A. Işık,et al.  Visfatin levels and intima-media thicknesses in rheumatic diseases , 2011, Clinical Rheumatology.

[13]  C. Miao,et al.  A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. , 2011, Analytical biochemistry.

[14]  V. Baichwal,et al.  Abstract 3526: Coadministration of nicotinic acid with the Nampt inhibitor MPC-9528 enhances antitumor activity in Naprt deficient cancer cells in culture and in xenografts , 2011 .

[15]  S. Eom,et al.  Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents. , 2011, European journal of medicinal chemistry.

[16]  M. Sehested,et al.  Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas , 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  M. Stumvoll,et al.  Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans , 2011, Diabetologia.

[18]  M. Sehested,et al.  Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase , 2010, BMC Cancer.

[19]  Brett R. Murphy,et al.  Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt). , 2010, Journal of medicinal chemistry.

[20]  R. Bräuer,et al.  In vivo molecular imaging of experimental joint inflammation by combined 18F-FDG positron emission tomography and computed tomography , 2010, Arthritis Research & Therapy.

[21]  H. Tilg,et al.  Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. , 2010, Mutation research.

[22]  Brett R. Murphy,et al.  Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound. , 2010, Chemistry & biology.

[23]  C. Sundberg,et al.  Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance , 2010, International journal of cancer.

[24]  D. Coppola,et al.  Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. , 2010, International journal of clinical and experimental pathology.

[25]  M. Sehested,et al.  A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor , 2010, Molecular Cancer Therapeutics.

[26]  B. Meskó,et al.  Open Access Research Article , 2022 .

[27]  R. Larsson,et al.  Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data , 2010, Cancer Chemotherapy and Pharmacology.

[28]  Brett R. Murphy,et al.  Abstract 3673: Identifying the target of an orphan compound: CB30865 is a Nampt inhibitor , 2010 .

[29]  V. Baichwal,et al.  Abstract LB-288: MPI-0486348: A novel inhibitor of nicotinamide phosphoribosyltransferase (Nampt) induces tumor regression in a preclinical model , 2010 .

[30]  P. Tak,et al.  Histone Deacetylase Inhibitors Suppress Inflammatory Activation of Rheumatoid Arthritis Patient Synovial Macrophages and Tissue , 2010, The Journal of Immunology.

[31]  Yi-Zhong Cai,et al.  Natural Phenolic Compounds From Medicinal Herbs and Dietary Plants: Potential Use for Cancer Prevention , 2009, Nutrition and cancer.

[32]  A. Ballestrero,et al.  Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE , 2009, PloS one.

[33]  Karine Gilbert,et al.  The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors , 2009, Molecular and Cellular Biology.

[34]  P. Raggi,et al.  Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis , 2009, Lupus.

[35]  T. Pincus,et al.  Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[36]  S. Eom,et al.  Crystal structure of Rattus norvegicus Visfatin/PBEF/Nampt in complex with an FK866-based inhibitor , 2009, Molecules and cells.

[37]  P. Sassone-Corsi,et al.  Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1 , 2009, Science.

[38]  A. Körner,et al.  Nampt: linking NAD biology, metabolism and cancer , 2009, Trends in Endocrinology & Metabolism.

[39]  C. Buechler,et al.  Peritoneal fluid adipokines: ready for prime time? , 2009, European journal of clinical investigation.

[40]  H. Randeva,et al.  Relationship Between Cerebrospinal Fluid Visfatin (PBEF/Nampt) Levels and Adiposity in Humans , 2009, Diabetes.

[41]  Véronique Kruys,et al.  Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner , 2009, Nature Medicine.

[42]  F. Cacciapaglia,et al.  Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors , 2009, The Journal of Rheumatology.

[43]  A. Schambach,et al.  NAMPT is essential for the G-CSF–induced myeloid differentiation via a NAD+–sirtuin-1–dependent pathway , 2009, Nature Medicine.

[44]  S. Imai.  The NAD World: A New Systemic Regulatory Network for Metabolism and Aging—Sirt1, Systemic NAD Biosynthesis, and Their Importance , 2009, Cell Biochemistry and Biophysics.

[45]  D. Hall,et al.  Regulation of Cartilage-specific Gene Expression in Human Chondrocytes by SirT1 and Nicotinamide Phosphoribosyltransferase* , 2008, Journal of Biological Chemistry.

[46]  Yuan Zhang,et al.  Extracellular Nampt Promotes Macrophage Survival via a Nonenzymatic Interleukin-6/STAT3 Signaling Mechanism* , 2008, Journal of Biological Chemistry.

[47]  R. Romero,et al.  Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition , 2008, Journal of perinatal medicine.

[48]  J. Isaacs,et al.  Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. , 2008, Rheumatology.

[49]  F. Andris,et al.  Nicotinamide Phosphoribosyl Transferase/Pre-B Cell Colony-Enhancing Factor/Visfatin Is Required for Lymphocyte Development and Cellular Resistance to Genotoxic Stress1 , 2008, The Journal of Immunology.

[50]  C. Brenner,et al.  Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. , 2008, Annual review of nutrition.

[51]  O. Leo,et al.  Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase/Visfatin Enzymatic Activity Identifies a New Inflammatory Pathway Linked to NAD , 2008, PloS one.

[52]  P. Canonico,et al.  Synthesis and Biological Evaluation of Isosteric Analogues of FK866, an Inhibitor of NAD Salvage , 2008, ChemMedChem.

[53]  E. Hoffman,et al.  Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. , 2008, Developmental cell.

[54]  F. Berenbaum,et al.  Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. , 2008, Arthritis and rheumatism.

[55]  Libin Zhou,et al.  Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. , 2008, Diabetes research and clinical practice.

[56]  L. Saltz,et al.  The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor , 2008, Investigational New Drugs.

[57]  J. Milbrandt,et al.  Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. , 2007, Cell metabolism.

[58]  Chenguang Wang,et al.  Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation , 2007, Trends in Endocrinology & Metabolism.

[59]  Dudley Lamming,et al.  Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival , 2007, Cell.

[60]  R. Gay,et al.  Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. , 2007, Arthritis and rheumatism.

[61]  S. Ito,et al.  Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[62]  M. Matsuda,et al.  Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. , 2007, Biochemical and biophysical research communications.

[63]  K. Bendtzen,et al.  Methotrexate induces poly(ADP‐ribose) polymerase‐dependent, caspase 3‐independent apoptosis in subsets of proliferating CD4+ T cells , 2007, Clinical and experimental immunology.

[64]  S. Imai,et al.  The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals , 2007, Current opinion in gastroenterology.

[65]  S. Tonstad,et al.  Increased Expression of Visfatin in Macrophages of Human Unstable Carotid and Coronary Atherosclerosis: Possible Role in Inflammation and Plaque Destabilization , 2007, Circulation.

[66]  J. Carrero,et al.  Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  A. Kaser,et al.  Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 , 2007, The Journal of Immunology.

[68]  Y. Obara,et al.  Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway , 2006, FEBS letters.

[69]  H. Randeva,et al.  Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. , 2006, The Journal of clinical endocrinology and metabolism.

[70]  S. Eom,et al.  Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. , 2006, Journal of molecular biology.

[71]  M. Yoo,et al.  Hypoxic induction of human visfatin gene is directly mediated by hypoxia‐inducible factor‐1 , 2006, FEBS letters.

[72]  C. Fielding,et al.  Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[73]  M. Zaidi,et al.  TNF regulates cellular NAD+ metabolism in primary macrophages. , 2006, Biochemical and biophysical research communications.

[74]  R. Busse,et al.  Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin , 2006, Diabetologia.

[75]  J. Gómez-Reino,et al.  Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[76]  S. Imai,et al.  Poly(ADP-ribose) Polymerase-1-dependent Cardiac Myocyte Cell Death during Heart Failure Is Mediated by NAD+ Depletion and Reduced Sir2α Deacetylase Activity* , 2005, Journal of Biological Chemistry.

[77]  M. Fasshauer,et al.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. , 2005, Diabetes.

[78]  R. Stevens,et al.  The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. , 2005, Structure.

[79]  J. Pickering,et al.  Pre–B-Cell Colony–Enhancing Factor Regulates NAD+-Dependent Protein Deacetylase Activity and Promotes Vascular Smooth Muscle Cell Maturation , 2005, Circulation research.

[80]  J. Koutcher,et al.  Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy , 2005, Clinical Cancer Research.

[81]  Chris Twelves,et al.  Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.

[82]  T. Standiford,et al.  Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. , 2005, American journal of respiratory and critical care medicine.

[83]  M. Matsuda,et al.  Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin , 2005, Science.

[84]  S. Imai,et al.  The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells* , 2004, Journal of Biological Chemistry.

[85]  J. Marshall,et al.  Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. , 2004, The Journal of clinical investigation.

[86]  B. Rattel,et al.  Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. , 2003, Anticancer research.

[87]  Max Hasmann,et al.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. , 2003, Cancer research.

[88]  G. Kroemer,et al.  Molecular mechanisms of sulfasalazine‐induced T‐cell apoptosis , 2002, British journal of pharmacology.

[89]  D. Gigot,et al.  Pre‐B‐cell colony‐enhancing factor, whose expression is up‐regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis , 2002, European journal of immunology.

[90]  S. Ognjanovic,et al.  Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. , 2002, American journal of obstetrics and gynecology.

[91]  Rolf Larsson,et al.  A Phase I study of CHS 828 in patients with solid tumor malignancy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  Jeffrey S. Smith.  Human Sir2 and the 'silencing' of p53 activity. , 2002, Trends in cell biology.

[93]  B. Rattel,et al.  WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. , 2002, Cancer research.

[94]  M. Höglund,et al.  Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro , 2001, Anti-cancer drugs.

[95]  L. Staudt,et al.  Signatures of the immune response. , 2001, Immunity.

[96]  S. Ognjanovic,et al.  Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. , 2001, Journal of molecular endocrinology.

[97]  R. Shea,et al.  Identification of a Plasmid-Encoded Gene fromHaemophilus ducreyi Which Confers NAD Independence , 2001, Journal of bacteriology.

[98]  M. Karlsson,et al.  In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. , 2001, Cancer letters.

[99]  D. Green,et al.  Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. , 2000, Immunology today.

[100]  J. Arends,et al.  A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization , 1999, FEBS letters.

[101]  T. Skov,et al.  CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. , 1999, Cancer research.

[102]  L. Brunton,et al.  A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus , 1999, British Journal of Cancer.

[103]  A. Jackman,et al.  Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. , 1998, Cytometry.

[104]  Hong-Wei Sun,et al.  Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor , 1998, The EMBO journal.

[105]  L. Binderup,et al.  Novel cyanoguanidines with potent oral antitumour activity , 1997 .

[106]  W. Howe,et al.  CXC Chemokines Connective Tissue Activating Peptide-III and Neutrophil Activating Peptide-2 are Heparin/Heparan Sulfate-degrading Enzymes (*) , 1995, The Journal of Biological Chemistry.

[107]  I McNiece,et al.  Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor , 1994, Molecular and cellular biology.

[108]  S. Dische,et al.  Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[109]  C. Lyttle,et al.  Leukocyte chemotactic activity of cyclophilin. , 1992, The Journal of biological chemistry.

[110]  Arsène Burny,et al.  The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase , 1988, Nature.

[111]  E. Pfefferkorn,et al.  Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. , 1986, Journal of interferon research.

[112]  A. Hoffer.  Treatment of arthritis by nicotinic acid and nicotinamide. , 1959, Canadian Medical Association journal.

[113]  D. Al-Zifzaf,et al.  Pre-B Cell Colony-Enhancing Factor as a Marker of Erosions in Rheumatoid Arthritis Patients , 2011 .

[114]  M. González-Gay,et al.  Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. , 2010, Clinical and experimental rheumatology.

[115]  R. Gebhardt,et al.  Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. , 2010, Biochemical and biophysical research communications.

[116]  C. Brenner,et al.  NAD+ metabolism in health and disease. , 2007, Trends in biochemical sciences.

[117]  J. Khan,et al.  Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.

[118]  Shyi-Jang Shin,et al.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. , 2006, The Journal of clinical endocrinology and metabolism.

[119]  R. Wall,et al.  Genes expressed during the IFNγ-induced maturation of pre-B cells , 2002 .

[120]  L. Tashima,et al.  Fetal membrane distention: I. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells. , 2000, American journal of obstetrics and gynecology.